JP2022518456A - 置換多環式カルボン酸、その類似体、およびそれらの使用法 - Google Patents

置換多環式カルボン酸、その類似体、およびそれらの使用法 Download PDF

Info

Publication number
JP2022518456A
JP2022518456A JP2021541219A JP2021541219A JP2022518456A JP 2022518456 A JP2022518456 A JP 2022518456A JP 2021541219 A JP2021541219 A JP 2021541219A JP 2021541219 A JP2021541219 A JP 2021541219A JP 2022518456 A JP2022518456 A JP 2022518456A
Authority
JP
Japan
Prior art keywords
butyl
tert
oxo
carboxylic acid
difluoromethoxy
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2021541219A
Other languages
English (en)
Japanese (ja)
Other versions
JP2022518456A5 (https=
JPWO2020150366A5 (https=
Inventor
シュアイ チェン
アンドリュー ジー． コール
ブルース ディー． ドーシー
イー ファン
ディミタール ビー． ゴチェフ
ラメシュ カカルラ
シャロン マリー カーク
ジョージ キンテロ
マイケル ジェイ． ソフィア
Original Assignee
アービュタス バイオファーマ コーポレイション
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by アービュタス バイオファーマ コーポレイション filed Critical アービュタス バイオファーマ コーポレイション
Publication of JP2022518456A publication Critical patent/JP2022518456A/ja
Publication of JP2022518456A5 publication Critical patent/JP2022518456A5/ja
Publication of JPWO2020150366A5 publication Critical patent/JPWO2020150366A5/ja
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/4375—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a six-membered ring having nitrogen as a ring heteroatom, e.g. quinolizines, naphthyridines, berberine, vincamine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/473—Quinolines; Isoquinolines ortho- or peri-condensed with carbocyclic ring systems, e.g. acridines, phenanthridines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/4738—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/4738—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/4745—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems condensed with ring systems having nitrogen as a ring hetero atom, e.g. phenantrolines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7088—Compounds having three or more nucleosides or nucleotides
    • A61K31/7105—Natural ribonucleic acids, i.e. containing only riboses attached to adenine, guanine, cytosine or uracil and having 3'-5' phosphodiester links
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7088—Compounds having three or more nucleosides or nucleotides
    • A61K31/713—Double-stranded nucleic acids or oligonucleotides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/20—Antivirals for DNA viruses
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/12—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains three hetero rings
    • C07D471/14—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Molecular Biology (AREA)
  • Virology (AREA)
  • Biochemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Biotechnology (AREA)
  • Engineering & Computer Science (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
JP2021541219A 2019-01-17 2020-01-15 置換多環式カルボン酸、その類似体、およびそれらの使用法 Pending JP2022518456A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201962793578P 2019-01-17 2019-01-17
US62/793,578 2019-01-17
PCT/US2020/013701 WO2020150366A1 (en) 2019-01-17 2020-01-15 Substituted polycyclic carboxylic acids, analogues thereof, and methods using same

Publications (3)

Publication Number Publication Date
JP2022518456A true JP2022518456A (ja) 2022-03-15
JP2022518456A5 JP2022518456A5 (https=) 2022-06-08
JPWO2020150366A5 JPWO2020150366A5 (https=) 2022-06-08

Family

ID=71613992

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2021541219A Pending JP2022518456A (ja) 2019-01-17 2020-01-15 置換多環式カルボン酸、その類似体、およびそれらの使用法

Country Status (15)

Country Link
US (1) US20220125771A1 (https=)
EP (1) EP3911653A4 (https=)
JP (1) JP2022518456A (https=)
KR (1) KR20210121044A (https=)
CN (1) CN113825756A (https=)
AU (1) AU2020208371A1 (https=)
BR (1) BR112021014079A2 (https=)
CA (1) CA3126102A1 (https=)
EA (1) EA202191967A1 (https=)
IL (1) IL284845A (https=)
MX (1) MX2021008646A (https=)
PH (1) PH12021551718A1 (https=)
SG (1) SG11202106965RA (https=)
TW (1) TW202033523A (https=)
WO (1) WO2020150366A1 (https=)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US10952978B2 (en) 2017-08-28 2021-03-23 Enanta Pharmaceuticals, Inc. Hepatitis B antiviral agents
US11702427B2 (en) 2018-03-12 2023-07-18 Arbutus Biopharma Corporation Substituted 2-pyridone tricyclic compounds, analogues thereof, and methods using same
CN110862390B (zh) 2018-08-28 2023-05-09 广东东阳光药业有限公司 稠合三环类化合物及其在药物中的应用
UY38383A (es) 2018-09-21 2020-04-30 Enanta Pharm Inc Heterociclos funcionalizados como agentes antivirales
CA3111046A1 (en) 2018-09-30 2020-04-02 Sunshine Lake Pharma Co., Ltd. Fused tetracyclic compounds and uses thereof in medicine
US11198693B2 (en) 2018-11-21 2021-12-14 Enanta Pharmaceuticals, Inc. Functionalized heterocycles as antiviral agents
US11738019B2 (en) 2019-07-11 2023-08-29 Enanta Pharmaceuticals, Inc. Substituted heterocycles as antiviral agents
US11236108B2 (en) * 2019-09-17 2022-02-01 Enanta Pharmaceuticals, Inc. Functionalized heterocycles as antiviral agents
WO2021188414A1 (en) 2020-03-16 2021-09-23 Enanta Pharmaceuticals, Inc. Functionalized heterocyclic compounds as antiviral agents
TW202304914A (zh) * 2021-04-05 2023-02-01 加拿大商愛彼特生物製藥公司 經取代之四環羧酸、其類似物及使用其之方法
WO2024038357A1 (en) * 2022-08-16 2024-02-22 Arbutus Biopharma Corporation Synthesis of substituted tetracyclic carboxylic acids and analogues thereof
CN115819200B (zh) * 2022-11-28 2023-08-29 辽宁科技学院 一种苊醌的合成方法

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2014121416A1 (en) * 2013-02-07 2014-08-14 Merck Sharp & Dohme Corp. Tetracyclic heterocycle compounds and methods of use thereof for the treatment of hepatitis c
WO2018073753A1 (en) * 2016-10-18 2018-04-26 Novartis Ag Fused tetracyclic pyridone compounds as antivirals

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
UA111756C2 (uk) * 2011-11-03 2016-06-10 Ф. Хоффманн-Ля Рош Аг Сполуки гетероарилпіридону та азапіридону як інгібітори тирозинкінази брутона
JP6506880B2 (ja) * 2015-07-27 2019-04-24 エフ．ホフマン−ラ ロシュ アーゲーＦ． Ｈｏｆｆｍａｎｎ−Ｌａ Ｒｏｃｈｅ Ａｋｔｉｅｎｇｅｓｅｌｌｓｃｈａｆｔ Ｂ型肝炎ウィルス感染症の治療および予防のための新規な四環式４−オキソ−ピリジン−３−カルボン酸誘導体
US20200270265A1 (en) * 2016-02-19 2020-08-27 Novartis Ag Tetracyclic pyridone compounds as antivirals
AR111419A1 (es) * 2017-04-27 2019-07-10 Novartis Ag Compuestos fusionados de indazol piridona como antivirales
CN110066278B (zh) * 2017-06-01 2021-06-08 广东东阳光药业有限公司 稠合三环类化合物及其在药物中的应用
TWI815887B (zh) * 2018-05-15 2023-09-21 美商愛彼特生物製藥股份有限公司 經取代的2,2'-雙嘧啶基化合物、其類似物及其使用方法

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2014121416A1 (en) * 2013-02-07 2014-08-14 Merck Sharp & Dohme Corp. Tetracyclic heterocycle compounds and methods of use thereof for the treatment of hepatitis c
WO2018073753A1 (en) * 2016-10-18 2018-04-26 Novartis Ag Fused tetracyclic pyridone compounds as antivirals

Non-Patent Citations (6)

* Cited by examiner, † Cited by third party
Title
BIOL. PHARM. BULL., vol. 26(4), JPN6023044982, 2003, pages 448 - 452, ISSN: 0005337053 *
DATABASE PUBCHEM, JPN6023044985, 8 April 2018 (2018-04-08), ISSN: 0005337057 *
JOURNAL OF ORGANIC CHEMISTRY, vol. 21, JPN6023044983, 1956, pages 1069 - 1071, ISSN: 0005337054 *
REGISTRY（STN）[ONLINE], JPN7023004099, 17 October 2023 (2023-10-17), ISSN: 0005337055 *
REGISTRY（STN）[ONLINE], JPN7023004100, 17 October 2023 (2023-10-17), ISSN: 0005337056 *
TETRAHEDRON LETTERS, vol. 58, JPN6023044979, 2017, pages 1373 - 1375, ISSN: 0005337052 *

Also Published As

Publication number Publication date
EP3911653A1 (en) 2021-11-24
WO2020150366A1 (en) 2020-07-23
AU2020208371A1 (en) 2021-07-15
CN113825756A (zh) 2021-12-21
KR20210121044A (ko) 2021-10-07
EP3911653A4 (en) 2022-11-02
PH12021551718A1 (en) 2022-03-28
MX2021008646A (es) 2021-10-26
BR112021014079A2 (pt) 2021-09-21
SG11202106965RA (en) 2021-08-30
IL284845A (en) 2021-08-31
CA3126102A1 (en) 2020-07-23
EA202191967A1 (ru) 2021-10-07
US20220125771A1 (en) 2022-04-28
TW202033523A (zh) 2020-09-16

Similar Documents

Publication Publication Date Title
JP2022518456A (ja) 置換多環式カルボン酸、その類似体、およびそれらの使用法
JP7113009B2 (ja) 置換ピリジノン含有三環式化合物およびそれを使用する方法
KR102705376B1 (ko) 화학적 화합물
CN106854205B (zh) 流感病毒复制抑制剂及其使用方法和用途
TWI801517B (zh) 經取代的2-吡啶酮三環化合物、其類似物及其使用方法
CN108976223B (zh) 稠合三环类化合物及其在药物中的应用
TWI815887B (zh) 經取代的2,2'-雙嘧啶基化合物、其類似物及其使用方法
JP2018531921A (ja) Ｂ型肝炎ウイルスコアタンパク質モジュレーター
KR20220088375A (ko) 피롤아미드 화합물 및 그 용도
JP2022513845A (ja) 置換アリールメチル尿素およびヘテロアリールメチル尿素、その類似体、ならびにそれらを使用する方法
WO2021188414A1 (en) Functionalized heterocyclic compounds as antiviral agents
TW202304914A (zh) 經取代之四環羧酸、其類似物及使用其之方法
US20240228504A1 (en) Substituted tricyclic amides, analogues thereof, and methods using same
WO2022143610A1 (zh) 新型酰胺吡咯类化合物及其在药物中的应用
TW202132285A (zh) 經取代異吲哚啉基2,2’-聯嘧啶基化合物、其類似物及使用其之方法
TW202138352A (zh) 經取代之雙環及三環脲類及醯胺類、其類似物及使用其之方法
HK40058308A (en) Substituted polycyclic carboxylic acids, analogues thereof, and methods using same
TW202321255A (zh) 經取代之三環醯胺及其類似物的合成
HK40012821A (en) Substituted pyridinone-containing tricyclic compounds, and methods using same

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20220531

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20221031

RD04 Notification of resignation of power of attorney

Free format text: JAPANESE INTERMEDIATE CODE: A7424

Effective date: 20230707

A977 Report on retrieval

Free format text: JAPANESE INTERMEDIATE CODE: A971007

Effective date: 20231026

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20231102

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20240603